Actinium Pharmaceuticals (ATNM) 15th Annual LD Micro Invitational 2025 summary

Strategic and clinical program updates

• Revitalized clinical programs and a new strategy are set to deliver multiple clinical, regulatory, and strategic milestones in 2025.

• Lead program Actimab-A is advancing in partnership with the National Cancer Institute, with new trials in frontline AML and solid tumors, including a pivotal phase II/III trial.

• Two clinical trials for Iomab-ACT will be active in 2025, with data expected in the second half of the year.

• Enhanced R&D infrastructure supports pipeline advancement, with two abstracts accepted for AACR presentation.

• Construction of an in-house radiotherapy manufacturing facility will begin this year.

Financial position and operational runway

• Ended 2024 with approximately $72.9 million in cash and cash equivalents.

• Funding is expected to support operations into mid-2027, enabling execution of strategic plans.

Clinical trial highlights and market opportunities

• Actimab-A is being added to venetoclax plus HMA therapy in newly diagnosed AML patients, with initial data expected by year-end.

• Expansion into solid tumors includes combinations with Keytruda and Opdivo, targeting CD33-expressing MDSCs to potentially resensitize tumors to PD-1 inhibitors.

• Multiple trials in non-small cell lung cancer and head and neck cancer are underway, with initial data anticipated in the second half of the year.